Tempus AIs ECG-AF Software Passes Multi-Site Validation, Backing FDA Clearance

Tempus AI, the precision‑medicine startup that listed on Nasdaq last June, has just confirmed that its AI‑powered electrocardiogram (ECG) tool—Tempus ECG‑AF—meets the performance bar set by the U.S. Food and Drug Administration (FDA) for clearance it already received in 2024.

The study, published in the journal Heart Rhythm, pulled data from three geographically diverse clinical sites. It enrolled 4,017 patients who were 65 years or older, had never been diagnosed with atrial fibrillation (AF) or flutter, and did not have a pacemaker or defibrillator implanted. Researchers combed through ECG recordings from each site and manually reviewed charts to confirm eligibility. The primary endpoint was whether a patient received a new AF diagnosis within one year—or, for those who stayed AF‑free, a full year of follow‑up.

What emerged was a clear winner: the ECG‑AF risk score consistently surpassed the FDA’s pre‑specified performance thresholds. In plain terms, the algorithm reliably flagged which older adults would develop AF in the next 12 months. The findings back Tempus’s claim that the software can serve as a dependable decision‑support tool across a range of clinical settings.

Brandon Fornwalt, senior vice president of cardiology at Tempus and a co‑author of the study, said the validation "marks an important step toward shifting cardiac care from late‑stage intervention to early risk detection." He added that the AI model’s steady performance across multiple sites underscores its potential to help clinicians spot hidden risks sooner—an advance that could enable earlier, more targeted diagnosis and care, and ultimately reduce serious complications such as stroke and heart failure.

Founded in 2015 by Eric Lefkofsky, Tempus AI has built a portfolio of next‑generation medical devices that harness data and artificial intelligence to improve diagnostics in oncology, cardiology, radiology, and mental health. The ECG‑AF device is the first FDA‑cleared ECG‑AI tool in that portfolio, marking a milestone for the company’s expansion into cardiovascular care.

For clinicians, the availability of a validated AI tool that can flag patients at high risk for AF could reshape workflows in both primary care and cardiology practices. Early identification of AF allows for timely initiation of anticoagulation therapy and other preventive measures, which can lower the risk of stroke and heart failure. Patients who are otherwise asymptomatic may benefit from closer monitoring and earlier intervention.

In short, the multi‑site validation confirms that Tempus ECG‑AF meets FDA performance criteria, reinforcing the company’s clearance and positioning the software as a practical tool for early AF risk detection in older adults.